New phase I trial methodology.

S Mani; M J Ratain

Home/Archive/PubMed

PubMed · 9129693

New phase I trial methodology.

S Mani·M J Ratain

View original source ↗Export metadata ↓

Abstract

Phase I trial design is constantly evolving to adapt to deficiencies in traditional methods and to accommodate newer rationally designed agents. This article discusses some of the important aspects of the design of phase I studies with particular reference to identifying new methods of safer but rapid dose escalation and reproducible end points such as maximum tolerated dose and recommended phase II dose. Given the explosion of rationally designed drugs capable of pathway specific inhibition, we also discuss potential strategies in designing trials with these agents. It is hoped that future strategies incorporate the existing methodologies with newer dose titration examples to complete phase I trials in a rapid and timely fashion.

Explore related subjects

Clinical Trials, Phase I as Topic Dose-Response Relationship, Drug Drug Administration Schedule Drugs, Investigational Humans Patient Selection Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S Mani, M J Ratain. 1997. New phase I trial methodology.. https://pubmed.ncbi.nlm.nih.gov/9129693/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

Much has been written recently about low productivity in the pharmaceutical industry and the high cost of drug development. Over a 10-year period ending in 2000, only approximately 11% of compounds tested in humans across 10 large pharmaceutical companies were eventually approved for marketing in the United States and/or Europe. Attrition was highest during phase II (62%) but still significant in phase III (45%) and at the time of registration (23%). Clearly, given the high cost and time required for clinical development, these late-stage failures are unsustainable.

Clinical Trials, Phase I as Topic↗

PubMed2007

Transgenic probiotica as drug delivery systems: the golden bullet?

Functional human proteins are constitutively produced in genetically modified bacteria that survive on human mucosal surfaces, to the benefit of the host. The successful Phase I clinical trial with IL-10-producing Lactococcus lactis for Crohn's disease has opened new avenues for the use of transgenic bacteria as delivery vehicles. The major advantage of this novel strategy is the avoidance of systemic side effects associated with conventional therapies. This methodology opens up an alternative method for local delivery of therapeutic proteins to various mucosal tissues.

Clinical Trials, Phase I as Topic↗

PubMed2006

Escalation, group and A + B designs for dose-finding trials.

In this paper, rules are given on how to construct escalation, A + B, and group designs for dose-finding trials. Operational characteristics of these designs are discussed and compared via simulations. Dose-finding designs for trials with ordinal toxicity outcome are considered.

Clinical Trials, Phase I as Topic↗